Results 151 to 160 of about 1,203 (200)

Genomic Insights of <i>Candida krusei</i>, an Emerging Fungal Pathogen With Intrinsic Antifungal Resistance. [PDF]

Open Forum Infect Dis
Jain K, Wadhwa K, Malik M, Haque S, Prieto MA, Kaur H.   +5 more
europepmc   +1 more source

Microbe Profile: <i>Candidozyma auris:</i> an emergent and resilient yeast and new antifungal strategies. [PDF]

Microbiology (Reading)
Ramage G, Sherry L, Kean R.
europepmc   +1 more source

First report of <i>Candida</i> (<i>Candidozyma) auris</i> infections in a human and a dolphin from the Dominican Republic: A One health perspective. [PDF]

Med Mycol Case Rep
Ferrara GA, Spruijtenburg B, Meijer EFJ, Meis JF, Ceballos-Garzon A, Caceres DH.   +5 more
europepmc   +1 more source

The novel second-generation triterpenoid SCY-247 maintains <i>in vitro</i> and <i>in vivo</i> activity against resistant <i>Candida glabrata</i>. [PDF]

Antimicrob Agents Chemother
Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Patterson HP, Patterson TF.   +5 more
europepmc   +1 more source

In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents

, 2019
Maiken Cavling Arendrup, Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary   +3 more
openalex   +2 more sources

Update 2016-2018 of the nationwide Danish fungaemia surveillance study:epidemiologic changes in a 15-year perspective [PDF]

, 2019
Antsupova, V. S., Arendrup, M. C., Astvad, K. M. T., Datcu, R., Dzajic, Esad, Gertsen, J. B., Hare, R., Johansen, H.K., Jørgensen, K. M., Knudsen, I.J.D., Kristensen, L., Møller, J. K., Risum, M., Rosenvinge, F. S., Røder, B. L., Schønheyder, Henrik   +15 more
core   +1 more source

Comprehensive strategies to defeat Candida auris - challenge and insight: A review. [PDF]

Medicine (Baltimore)
Zhang J, Zhong L, Chen C, Ye L, Cao F, Xia H, Hong Y.   +6 more
europepmc   +1 more source

Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

, 2019
Annie Lee, Brendan Prideaux, Matthew Zimmerman, Claire Carter, Stephen Barat, David Angulo, Véronique Dartois, David S. Perlin, Yanan Zhao   +8 more
openalex   +2 more sources

A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

Oluwatosin Goje, Nkechi Azie, David Angulo, Ryan Sobel, Paul Nyirjesy, Jack D. Sobel   +5 more
openalex   +1 more source

The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives. [PDF]

Curr Res Microb Sci
Souza CM, Bezerra BT, Mellon DA, de Oliveira HC.   +3 more
europepmc   +1 more source